23-Jan-2026
Health Catalyst Announces Chief Commercial Officer Transition Plan
TipRanks (Fri, 23-Jan 5:25 PM ET)
PRNewswire (Tue, 2-Dec 6:59 AM ET)
Health Catalyst to Participate in Upcoming Investor Conferences
Globe Newswire (Fri, 14-Nov 4:14 PM ET)
PRNewswire (Mon, 10-Nov 4:03 PM ET)
UnityPoint Health to Unlock Next Phase of Analytics Innovation by Activating Health Catalyst Ignite
PRNewswire (Mon, 10-Nov 4:03 PM ET)
Health Catalyst Reports Third Quarter 2025 Results
Globe Newswire (Mon, 10-Nov 4:03 PM ET)
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Health Catalyst trades on the NASDAQ stock market under the symbol HCAT.
As of January 23, 2026, HCAT stock price declined to $2.25 with 649,418 million shares trading.
HCAT has a beta of 1.22, meaning it tends to be more sensitive to market movements. HCAT has a correlation of 0.12 to the broad based SPY ETF.
HCAT has a market cap of $159.14 million. This is considered a Micro Cap stock.
Last quarter Health Catalyst reported $76 million in Revenue and $.06 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.04.
In the last 3 years, HCAT traded as high as $15.87 and as low as $2.02.
The top ETF exchange traded funds that HCAT belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
HCAT has underperformed the market in the last year with a price return of -61.1% while the SPY ETF gained +14.2%. HCAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.5% and -8.9%, respectively, while the SPY returned +2.9% and -0.7%, respectively.
HCAT support price is $2.26 and resistance is $2.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCAT shares will trade within this expected range on the day.